ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of High Dose Atorvastatin in Patients With Surgical Aortic Stenosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00811330
Recruitment Status : Unknown
Verified June 2015 by University Hospital, Strasbourg, France.
Recruitment status was:  Recruiting
First Posted : December 19, 2008
Last Update Posted : June 19, 2015
Sponsor:
Information provided by (Responsible Party):
University Hospital, Strasbourg, France

December 17, 2008
December 19, 2008
June 19, 2015
December 2008
January 2018   (Final data collection date for primary outcome measure)
♦ Phase I: To study changes on inflammatory markers after aortic valve replacement. ♦ Phase II: To study changes in left ventricular mass at the end of the study (12 months). [ Time Frame: 1 year ]
Same as current
Complete list of historical versions of study NCT00811330 on ClinicalTrials.gov Archive Site
Phase I: To study changes on mitochondrial function, reactive oxygen species, and perioperative systolic and diastolic functions. Phase II: To study changes on clinical status, systolic and diastolic functions during the one-year follow-up. [ Time Frame: 1 year ]
Same as current
Not Provided
Not Provided
 
Effects of High Dose Atorvastatin in Patients With Surgical Aortic Stenosis
Interest of Statin in Surgical Aortic Stenosis: From Myocardial Preconditioning to Ventricular Reverse Remodeling.
The purpose of the study is to see if statin therapy will optimize myocardial response to cardiopulmonary bypass during aortic valve replacement (AVR) for aortic valve stenosis (AVS) (Phase I) and optimize left ventricular reverse remodeling following AVR (Phase II). Preliminary evidence indicates that perioperative statin therapy reduce mortality and morbidity following cardiac surgery. Pleiotropic effects of statins may induce myocardial preconditioning and optimize myocardial and systemic responses to cardiopulmonary bypass during AVR. Furthermore statin therapy after AVR may contribute to an optimal left ventricular reverse remodeling.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
  • Aortic Valve Stenosis
  • Ventricular Hypertrophy
Drug: Atorvastatin 80 mg
Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
  • Experimental: 1: Atorvastatin 80 mg.
    Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
    Intervention: Drug: Atorvastatin 80 mg
  • No Intervention: 2: No Atrovastatine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
60
Same as current
January 2018
January 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age > or = 70 years and < 80 years
  • Severe aortic valve stenosis
  • Indication for aortic valve replacement by bioprothesis
  • Ejection fraction > or = 50%
  • Without treatment with statin- No renal failure
  • Informed consent signed

Exclusion Criteria:

  • Ischemic heart disaese
  • Concomitant surgery to aortic valve replacement
  • Emergency surgery- Known intolerance for statin
  • Pregnant woman
Sexes Eligible for Study: All
70 Years to 80 Years   (Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT00811330
3963
No
Not Provided
Not Provided
University Hospital, Strasbourg, France
University Hospital, Strasbourg, France
Not Provided
Principal Investigator: Michel KINDO, MD Hôpitaux Universitaires de Strasbourg
University Hospital, Strasbourg, France
June 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP